Cystine

Cystine

SCHEMBL127805

N[C@H](CSSC[C@H](N)C(=O)O)C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.50
SLC7A11 Q9UPY5 1/20 0.50
ARG1 P05089 1/20 0.50
ARG2 P78540 1/20 0.50
NOS2 P35228 3/20 0.48
NOS1 P29475 2/20 0.48
NOS3 P29474 1/20 0.48
GRIK1 P39086 4/20 0.48
GRIK2 Q13002 4/20 0.48
GRM1 Q13255 2/20 0.48
GRM2 Q14416 2/20 0.48
GSR P00390 2/20 0.46
SLC1A1 P43005 2/20 0.46
SLC7A5 Q01650 1/20 0.46
GRM8 O00222 1/20 0.46
GRM6 O15303 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
CYP1A2 P05177 1/20 0.46
GRM5 P41594 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cystine SCHEMBL30540421 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL5018669 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL8332356 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL10224 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL8332353 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL21114356 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL222059 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL10225 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL8332360 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL10335533 1.00 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630411-A1 FORMULATION FOR AROMATIZING A FOOD PRODUCT Döhler GmbH (DE) 2025-10-15 EP claimed
WO-2024120760-A1 FORMULATION FOR AROMATIZING A FOOD PRODUCT DÖHLER GmbH (DE) 2024-06-13 WO claimed
EP-2621462-B1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR PROCTER & GAMBLE (US) 2020-02-12 EP claimed
EP-2621462-A1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR The Procter and Gamble Company (US) 2013-08-07 EP claimed
WO-2012044728-A1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR THE PROCTER & GAMBLE COMPANY (US) 2012-04-05 WO claimed
US-20120082628-A1 Oral Care Compositions With Improved Flavor THE PROCTER & GAMBLE COMPANY 2012-04-05 US claimed
EP-4630411-A1 FORMULATION FOR AROMATIZING A FOOD PRODUCT Döhler GmbH (DE) 2025-10-15 EP disclosed
EP-3383502-B1 ORAL CARE PRODUCT AND METHODS OF USE AND MANUFACTURE THEREOF COLGATE PALMOLIVE CO (US) 2025-03-05 EP disclosed
WO-2024120760-A1 FORMULATION FOR AROMATIZING A FOOD PRODUCT DÖHLER GmbH (DE) 2024-06-13 WO disclosed
US-20230310461-A1 Compositions and Methods for Treatment of Prediabetes CROSS III WILLIAM H (US) 2023-10-05 US disclosed
US-20230310461-A1 Compositions and Methods for Treatment of Prediabetes CROSS III WILLIAM H (US) 2023-10-05 US disclosed
US-20230201246-A1 METAL COMPOSITIONS AND METHODS OF USE THEREOF UNIVERSITY OF MASSACHUSETTS 2023-06-29 US disclosed
US-20230201246-A1 METAL COMPOSITIONS AND METHODS OF USE THEREOF UNIVERSITY OF MASSACHUSETTS 2023-06-29 US disclosed
WO-2007098466-A2 SEGMENTED DEGRADABLE POLYMERS AND CONJUGATES MADE THEREFROM NEKTAR THERAPEUTICS AL, CORPORATION (US) 2007-08-30 WO disclosed
EP-0245362-A4 SYNTHETIC PEPTIDES AND USE FOR DIAGNOSIS AND VACCINATION FOR AIDS AND ARC. SOUTHWEST FOUND BIOMED RES (US) 1990-04-10 EP disclosed
EP-0276279-A4 COMPOSITION OF MATTER AND METHOD OF IMMUNIZING AGAINST VIRAL CAUSATIVE AGENTS OF AIDS AND ARC. SOUTHWEST FOUND BIOMED RES (US) 1990-01-08 EP disclosed
EP-0276279-A1 COMPOSITION OF MATTER AND METHOD OF IMMUNIZING AGAINST VIRAL CAUSATIVE AGENTS OF AIDS AND ARC SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1988-08-03 EP disclosed
WO-1988000471-A1 COMPOSITION OF MATTER AND METHOD OF IMMUNIZING AGAINST VIRAL CAUSATIVE AGENTS OF AIDS AND ARC SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1988-01-28 WO disclosed
EP-0245362-A1 SYNTHETIC PEPTIDES AND USE FOR DIAGNOSIS AND VACCINATION FOR AIDS AND ARC. SOUTHWEST FOUND BIOMED RES (US) 1987-11-19 EP disclosed
WO-1987002775-A1 SYNTHETIC PEPTIDES AND USE FOR DIAGNOSIS AND VACCINATION FOR AIDS AND ARC SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1987-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230201246-A1 METAL COMPOSITIONS AND METHODS OF USE THEREOF SOD1, SOD3, SLC30A5 PTGS1 2350/4885SLC7A11 1265/4885ARG1 177/4885
US-20230310461-A1 Compositions and Methods for Treatment of Prediabetes GPX1, GPX4, NFE2L2 PTGS1 820/4885SLC7A11 1135/4885ARG1 2269/4885
US-20120082628-A1 Oral Care Compositions With Improved Flavor TRPA1, TAS2R40, TAS2R30 PTGS1 2908/4885SLC7A11 3887/4885ARG1 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.